Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Axcelead Now Independent from Takeda
April 3, 2019
- Kowa Sues Towa over Livalo Generics, Demands 4.5 Billion Yen in Additional Damages
April 3, 2019
- Telomelysin/Keytruda Combo Shows No Dose-Limiting Toxicities in Interim PIa Data: Oncolys
April 3, 2019
- Xospata Significantly Extends OS in PIII Study in FLT3-Mutated AML: Astellas
April 3, 2019
- Sumitomo Dainippon Files Rethio for Conditioning Treatment Prior to HSCT for Malignant Lymphoma
April 3, 2019
- Nichi-Iko Takes Over Futhan from Torii
April 2, 2019
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Entyvio SC Form Now under EMA Review: Takeda
April 2, 2019
- Chugai Offloading Antiulcer Drug Ulcerlmin to Fuji Chemical
April 2, 2019
- Novel Antibiotic Cefiderocol Accepted for EMA Review: Shionogi
April 2, 2019
- Mundipharma, Maruishi to Copromote Tapenta from June
April 2, 2019
- GSK, Daiichi Sankyo Vaccine Joint Venture Dissolved
April 2, 2019
- Mochida Aims at 108 Billion Yen Sales in FY2021: New 3-Year Biz Plan
April 2, 2019
- Pfizer, Mochida Tie Up for Antidepressant Desvenlafaxine in Japan
April 2, 2019
- Takeda Files Adcetris for PTCL, Pediatric Use in Japan
April 1, 2019
- Daiichi Sankyo Bags US$6.9 Billion AstraZeneca Pact for Cancer Hopeful DS-8201, Announces CEO Change
April 1, 2019
- Safety Monitoring Board Backs PIII Continuation for Elenbecestat: Eisai
April 1, 2019
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Takeda Spin-Off Startup Chordia Raises 3 Billion Yen to Fund Oncology R&D
April 1, 2019
- Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…